Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A composition for the treatment of proliferative disorders, said composition comprising an antineoplastic agent selected from the group consisting of paclitaxel and gemcitabine and a compound having the formula:





,



,

or



and the pharmaceutically acceptable salts thereof. [[;]]

~~wherein~~

~~R is a member selected from the group consisting of hydrogen and substituted or unsubstituted (C_1-C_{10})alkyl; and~~

~~Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.~~

Claims 2-3 (canceled).

Claim 4 (currently amended): A composition in accordance with claim 1 wherein said antineoplastic agent is ~~selected from the group consisting of doxorubicin, daunorubicin, gemcitabine and~~ paclitaxel.

Claim 5 (currently amended): A composition in accordance with claim 1, wherein said antineoplastic agent is gemcitabine. ~~or paclitaxel~~.

Claim 6 (currently amended): A composition in accordance with claim 1, wherein ~~R is hydrogen or unsubstituted (C_1-C_4)alkyl.~~ the formula is



Claim 7 (currently amended): A composition in accordance with claim 1, wherein ~~Ar is a substituted phenyl group.~~ the formula is



Claim 8 (currently amended): A composition in accordance with claim [[7]] 1, wherein ~~said substituents on said phenyl group are selected from the group consisting of halogen, $(C_1$-$C_4)$alkoxy, $(C_1$-$C_4)$alkyl, $-OPO_3H_2$, $-OC(O)R'$, $-NR'R''$, $-CO_2R'$, $-CONR'R''$, $-C(O)R'$, $-OC(O)NR'R''$, $-NR''C(O)R'$, $-NR''C(O)_2R'$, $-NR'-C(O)NR''R'''$, perfluoro$(C_1$-$C_4)$alkoxy, and perfluoro$(C_1$-$C_4)$alkyl, wherein R', R'' and R''' is each independently hydrogen or $(C_1$-$C_4)$alkyl.~~ the formula is



Claims 9 -10 (canceled).

Claim 11 (currently amended): A method for the treatment of cancer ~~a proliferative disorder~~, comprising administering to a subject in need of such treatment an effective amount of a composition of claim 1.

Claim 12 (currently amended): A method in accordance with claim 11, wherein the antineoplastic agent is gemcitabine and the formula is



~~compound is selected from the group consisting of:~~





Claims 13-14 (canceled).

Claim 15 (currently amended): A method in accordance with claim 12, wherein said antineoplastic agent is ~~selected from the group consisting of doxorubicin, daunorubicin, gemcitabine and~~ paclitaxel.

Claim 16 (currently amended): A method in accordance with claim 12, wherein said antineoplastic agent is gemcitabine ~~or paclitaxel~~.

Claim 17 (currently amended): A method for the treatment of cancer ~~a proliferative disorder~~, comprising administering to a subject in need of such treatment:

i) a first amount of an antineoplastic agent selected from the group consisting of paclitaxel and gemcitabine; and

ii) a second amount of a compound of formula:







or



and the pharmaceutically acceptable salts thereof~~; wherein~~

~~R is a member selected from the group consisting of hydrogen and substituted or unsubstituted (C_1-C_{10})alkyl; and~~

~~Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;~~

wherein said first amount and said second amount, in combination, are effective to treat said cancer ~~proliferative disorder.~~

Claim 18 (currently amended): A method in accordance with claim 17, wherein said antineoplastic agent is gemcitabine and said formula is ~~compound is selected from the group consisting of~~





and



Claims 19-20 (canceled).

Claim 21 (currently amended): A method in accordance with claim 18, wherein said antineoplastic agent is ~~selected from the group consisting of doxorubicin, daunorubicin, gemcitabine and~~ paclitaxel.

Claim 22 (currently amended): A method in accordance with claim 18, wherein said antineoplastic agent is gemcitabine ~~or paclitaxel~~.

Claim 23 (original): A method in accordance with claim 18, wherein said antineoplastic agent is administered prior to said compound.

Claim 24 (original): A method in accordance with claim 18, wherein said antineoplastic agent is administered after said compound.

Claim 25 (original): A method in accordance with claim 18, wherein said antineoplastic agent is administered simultaneously with said compound.

Claim 26 (new): A method in accordance with claim 17, wherein the cancer is mammary cancer.

Claim 27 (new): A method in accordance with claim 17, wherein the subject is human.

Claim 28 (new): A method in accordance with claim 11, wherein the subject has mammary cancer.

Claim 29 (new): A method in accordance with claim 11, wherein the subject is human.

Claim 30 (new): A method in accordance with claim 11, wherein the formula is



and the antineoplastic agent is gemcitabine.

Claim 31 (new): A method in accordance with claim 11, wherein the formula is



and the antineoplastic agent is gemcitabine.

Claim 32 (new): A method in accordance with claim 17, wherein the formula is



and the antineoplastic agent is gemcitabine.

Claim 33 (new): A method in accordance with claim 17, wherein the formula is



and the antineoplastic agent is gemcitabine.

Claim 34 (new): A composition of claim 8, wherein the antineoplastic agent is gemcitabine.